大日本住友製薬（4506） – Notice of Establishment of Holding Company in China

March 30, 2022 Sumitomo Dainippon Pharma Co., Ltd. Notice of Establishment of Holding Company in China Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that its Board of Directors resolved at a meeting held on February 28, 2022, to establish a holding company in China as a wholly owned subsidiary. 1. Objective of the establishment The Company decided to establish a holding company, “Sumitomo Pharma (China) Co., Ltd.” in China as a wholly owned subsidiary to manage and enhance our China business. 2. Outline of the subsidiary (1) Company name: Sumitomo Pharma (China) Co., Ltd. (2) Location: 7th Floor, Tower A, China Overseas International Center, Lane 838, South Huangpi Road, Huangpu District, Shanghai (3) Representative: Yoshitaka Koketsu (Chairman of the Board) (4) Function: Manage the Company’s China business as a holding company The impact of the establishment of the holding company on the Company’s consolidated financial ・General management ・Shared service ・Cash pool (5) Share capital: 30M US dollars (6) Establishment: May 2022 (TBD) (7) Ownership: 100% owned by the Company (8) Fiscal year-end: December 31 (9) Number of employees: 15（TBD） 3. Future outlook results is minimal. Contact: Corporate Communications Sumitomo Dainippon Pharma Co., Ltd. TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)